Stock comparison
Genmab A/S
Moderna
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MRNA
Moderna
Market cap
$18.6B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MRNA | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 21F | GMAB |
| Benjamin Graham | 64C | 47D | GMAB |
| Philip Fisher | 48D | 27F | GMAB |
| Peter Lynch | 25F | 4F | GMAB |
| Joel Greenblatt | 76B | 2F | GMAB |
| Charlie Munger | 68C | 19F | GMAB |
| Terry Smith | 71C | 19F | GMAB |
Side-by-side metrics
| Metric | GMAB | MRNA |
|---|---|---|
| Market cap | $16.5B | $18.6B |
| P/E (TTM) | 6.2x | - |
| EV/EBIT | 12.0x | - |
| ROIC (TTM) | 43.78% | -37.32% |
| Gross margin | 93.88% | -13.89% |
| Net margin | 18.23% | -143.55% |
| Revenue CAGR 5y | -18.45% | -42.46% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs -37.32%+185%
- Gross margin93.88%vs -13.89%+115%
- Net margin18.23%vs -143.55%+113%
- Debt / Equity0.1xvs 0.2x+58%
MRNA leads on
- P/E (TTM)-vs 6.2x+199%
- EV/EBIT-vs 12.0x+151%
- Market cap$18.6Bvs $16.5B+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.